{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:30:05Z","timestamp":1791088205195,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6,15]]},"DOI":"10.2146\/ajhp130592","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T22:12:50Z","timestamp":1401228770000},"page":"1001-1008","source":"Crossref","is-referenced-by-count":21,"title":["Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia"],"prefix":"10.1093","volume":"71","author":[{"given":"Kyle A.","family":"Davis","sequence":"first","affiliation":[{"name":"Jackson Memorial Hospital, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta A.","family":"Miyares","sequence":"additional","affiliation":[{"name":"Jackson Memorial Hospital, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"issue":"suppl 3","key":"2019041211013301300_b1-0711001","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jacl.2013.03.003","article-title":"Emerging low-density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors","volume":"7","author":"Goldberg","year":"2013","journal-title":"J Clin Lipidol"},{"key":"2019041211013301300_b2-0711001","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J Manag Care Pharm"},{"key":"2019041211013301300_b3-0711001","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"2019041211013301300_b4-0711001","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MOL.0b013e32836308bc","article-title":"Recent advances in the treatment of homozygous familial hypercholesterolaemia","volume":"24","author":"Marais","year":"2013","journal-title":"Curr Opin Lipidol"},{"issue":"suppl 3","key":"2019041211013301300_b5-0711001","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association expert panel on familial hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"key":"2019041211013301300_b6-0711001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1388-1981(00)00049-4","article-title":"Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly","volume":"1486","author":"Gordon","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"2019041211013301300_b7-0711001","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/ncpcardio1251","article-title":"Microsomal triglyceride transfer protein inhibition\u2014friend or foe?","volume":"5","author":"Joy","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2019041211013301300_b8-0711001","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MOL.0b013e3282f169c6","article-title":"New targets and emerging therapies for reducing LDL cholesterol","volume":"18","author":"Lilly","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"2019041211013301300_b9-0711001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/187221412799015290","article-title":"Emerging therapies for dyslipidemia: known knowns and known unknowns of MTP inhibitors","volume":"6","author":"Raval","year":"2012","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"2019041211013301300_b10-0711001","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin Ther"},{"key":"2019041211013301300_b11-0711001","unstructured":"Food and Drug Administration. Briefing document: NDA 203858. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM323841.pdf (accessed 2013 Aug 25)."},{"key":"2019041211013301300_b12-0711001","unstructured":"Center for Drug Evaluation and Research, Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s). Application number 203858 Orig1s000. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203858Orig1s000ClinpharmR.pdf (accessed 2013 Aug 25)."},{"key":"2019041211013301300_b13-0711001","unstructured":"ClinicalTrials.gov. Study to determine the intra-subject variability of pharmacokinetics of lomitapide in healthy subjects (NCT01915771). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01915771?term=lomitapide&rank=5 (accessed 2013 Aug 30)."},{"key":"2019041211013301300_b14-0711001","unstructured":"ClinicalTrials.gov. Phase I study of the safety, tolerability, PK & PD of lomitapide in Japanese and Caucasian subjects with elevated LDL-C (NCT01760187). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01760187?term=lomitapide&rank=2 (accessed 2013 Aug 30)."},{"key":"2019041211013301300_b15-0711001","volume-title":"Juxtapid (lomitapide) package insert","year":"2012"},{"key":"2019041211013301300_b16-0711001","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"2019041211013301300_b17-0711001","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0005-2760(96)00168-3","article-title":"Microsomal triglyceride transfer protein","volume":"1345","author":"Wetterau","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"2019041211013301300_b18-0711001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2019041211013301300_b19-0711001","doi-asserted-by":"crossref","first-page":"778","DOI":"10.7326\/0003-4819-140-10-200405180-00007","article-title":"The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial","volume":"140","author":"Stern","year":"2004","journal-title":"Ann Intern Med"},{"key":"2019041211013301300_b20-0711001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-2275(20)39776-5","article-title":"In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism","volume":"35","author":"Ikewaki","year":"1994","journal-title":"J Lipid Res"},{"key":"2019041211013301300_b21-0711001","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/jama.280.23.2001","article-title":"Intensive lifestyle changes for reversal of coronary heart disease","volume":"280","author":"Ornish","year":"1998","journal-title":"JAMA"},{"key":"2019041211013301300_b22-0711001","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a singlearm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"2019041211013301300_b23-0711001","unstructured":"ClinicalTrials.gov. Evaluate safety and efficacy of AEGR-733 and atorvastatin vs atorvastatin monotherapy in hypercholesterolemia. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00690443?term=lomitapide&rank=9 (accessed 2013 Aug 30)."},{"key":"2019041211013301300_b24-0711001","unstructured":"ClinicalTrials.gov. Long term, follow-on study of lomitapide in patients with homozygous familial hypercholesterolemia. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00943306?term=lomitapide&rank=1 (accessed 2013 Aug 30)."},{"key":"2019041211013301300_b25-0711001","author":"Tuteja","year":"2013","journal-title":"Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia"},{"key":"2019041211013301300_b26-0711001","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"2019041211013301300_b27-0711001","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2019041211013301300_b28-0711001","unstructured":"Feuerstein A , for TheStreet, Inc. Aegerion CEO speaks on Juxtapid launch, orphan drug pricing and competition. www.thestreet.com\/story\/11826405\/1\/aegerion-ceo-speaks-on-juxtapid-launch-orphan-drug-pricing-and-competition.html (accessed 2013 Nov 6)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/12\/1001\/28372742\/ajhp1001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T23:53:18Z","timestamp":1649116398000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/12\/1001\/5110890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,15]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,6,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130592","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,6,15]]},"published":{"date-parts":[[2014,6,15]]}}}